Balyasny Asset Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Balyasny Asset Management’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-596,407	Closed	-$24.4M	–	3278
2024 Q2	$24.4M	Sell	596,407 -480,808	-45%	-$20M	0.04%	534
2024 Q1	$45.5M	Sell	1,077,215 -864,000	-45%	-$36.3M	0.08%	331
2023 Q4	$82.3M	Buy	1,941,215 +1,911,419	+6,415%	+$54.9M	0.15%	152
2023 Q3	$650K	Sell	29,796 -80,953	-73%	-$2.03M	﹤0.01%	1677
2023 Q2	$3.52M	Sell	110,749 -238,853	-68%	-$7.33M	0.01%	1185
2023 Q1	$8.53M	Buy	+349,602	New	+$10.3M	0.02%	840

Other funds holding CERE

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Balyasny Asset Management's CERE Position: Q3 2024 in Review

Balyasny Asset Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 596,407 shares — an estimated $24.4M sold.

Balyasny Asset Management first reported a position in CERE in Q1 2023 and held it in 6 quarters. The position peaked at $82.3M in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

Balyasny Asset Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Balyasny Asset Management sold 596,407 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $24.4M.
Balyasny Asset Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2023 and held it in 6 quarters.
Balyasny Asset Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $82.3M in Q4 2023.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Balyasny Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.